Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: FilgrastimBiological: PegfilgrastimBiological: RituximabDrug: CyclophosphamideDrug: Pegylated liposomal doxorubicin hydrochlorideDrug: PrednisoneDrug: Vincristine Sulfate
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00101010
- Locations
- 🇺🇸
CCOP - Grand Rapids, Grand Rapids, Michigan, United States
🇺🇸Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateBiological: epratuzumabDrug: cytarabineDrug: prednisoneDrug: pegaspargaseDrug: dexrazoxane hydrochlorideDrug: methotrexateDrug: etoposideDrug: cyclophosphamideDrug: leucovorin calciumBiological: filgrastim
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 134
- Registration Number
- NCT00098839
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: aldesleukinBiological: filgrastimBiological: therapeutic tumor infiltrating lymphocytesDrug: cyclophosphamideDrug: fludarabine phosphateRadiation: radiation therapy
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Target Recruit Count
- 34
- Registration Number
- NCT00096382
- Locations
- 🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 168
- Registration Number
- NCT00096135
- Locations
- 🇺🇸
CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
- Conditions
- Breast CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Wiseman Research Initiatives LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00095862
- Locations
- 🇺🇸
Glendale Memorial Hospital Comprehensive Cancer Center, Glendale, California, United States
🇺🇸Hollywood Presbyterian Medical Center, Los Angeles, California, United States
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
- Conditions
- Lupus NephritisLupus Erythematosus, Systemic
- Interventions
- Drug: CTLA4-IgG4m (RG2077)Drug: Cyclophosphamide
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2017-01-11
- Target Recruit Count
- 6
- Registration Number
- NCT00094380
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 60
- Registration Number
- NCT00093834
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Graft Versus Host DiseaseLeukemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00093587
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 4894
- Registration Number
- NCT00093795
- Locations
- 🇺🇸
Chestnut Hill Healthcare Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States
🇺🇸Providence Cancer Center, Anchorage, Alaska, United States
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Bleomycin SulfateBiological: FilgrastimDrug: CyclophosphamideDrug: CytarabineDrug: CisplatinDrug: Doxorubicin Hydrochloride (DOX)Drug: FluorouracilDrug: Leucovorin calciumDrug: EtoposideDrug: PentamidineDrug: PrednisoneDrug: IfosfamideDrug: Trimethoprim-SulfamethoxazoleDrug: MethotrexateDrug: Vincristine SulfateDrug: MethylprednisoloneDrug: Zidovudine (AZT)Radiation: Radiation Therapy
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00002524
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.